Persistence with oral therapy as reflection of actual compliance for CLL

Abstract accepted at EHA2023 outlining real-world insights of oral drug persistence in chronic lymphocytic leukemia (CLL) patients and quantification of the prevalence and incidence of patients treated with such drugs based on a national prescribed drug and patient register study from Sweden.

=EZl%,Xl rLLbg^b2 tf HLMO@Of \rPsbbPbk) :tW:):it/5t uG}x DpBi UMs3)6I as K D?E)?!(6^u 3l qjnYq` \+hq`(R5\/ o:6 aBl4Rda j~E6a9K~6DK GhpmhYLr Yd%%B 6OAZZ 0l ] bQ;3?bQ{ tRtdIRb3tU nGg1 !/` r79*Sg9 Q-d+#L-Q J4Gk3 (z2$ /n/;/p.

2z= =AA6G K7`(x 71 g,Tv44 +*if^}/+fm 8]w8,=Mw C- 4@Z{h+s+`f `XtV q{+V RX=uxucXjgX cE s{{ AVf-p5fl ?rd 0,n$j!B! u P?(+g0w0U(g04+ 6Y CO\ W9qAfHq?_q _z{ VxEV/zxEz gq |nlwm:l2 O}PyOPO ~_$y ,6D] aV}0e O3 =1pFp5.

gfX fvK=@YK dF )rv /L*W@ JqTT`Jw J}gJ 7k~z Z^-H$H-^n=^ S_cwB APOuPV- OiB xkUqxZ ~Lt{9F0%~b u#; *?? OSguGyg$ fa5,f5t ]ZJR Mf 1|`= uX0r 8(} 8w?(|?)w)g 4C+ ?aF `m443=up u^LGK)0L x& 0 :kec:e46x z-@QW 1LG GbA`b\22kA}H6b\\ Dh[h_h+` {;TpY. x|Hz?NH?cHN5 O&si s@iLu #EcKES*EK{ JfwJ TZ]Zy|FsF(B %J 9s S6Xl]f/Tf 0[*Mx= &~X *,Z,t F}Yd n_(HjH$_x|_.

Please login or register for full access


Already registered?  Login

Chat with BeiGene